The trademark application MYADMIA was filed by Takeda Pharmaceuticals International AG, a corporation established under the laws of the Swiss Confederation (the "Applicant"). The application was published for oppositions on October 6, 2022, and it was registered by office on January 13, 2023 without any oppositions.
The application was filed in English (German was selected as the second language).